BPH

BPH
Name	Benign prostatic hyperplasia
Field	Urology
Synonyms	Benign prostatic hypertrophy; nodular hyperplasia

BPH

Benign prostatic hyperplasia is a common nonmalignant enlargement of the prostate gland that affects aging men, often presenting with lower urinary tract symptoms. It is a major cause of urinary morbidity in primary care, urology clinics, and geriatrics, and has implications for surgical practice, public health policy, and pharmaceutical development. Historical descriptions in surgical literature and population studies have shaped contemporary screening, diagnostic, and therapeutic approaches.

Overview

BPH is characterized by nodular proliferation of epithelial and stromal elements within the transitional zone of the prostate, producing urethral compression and bladder outlet obstruction. Classic work by investigators in institutions such as Mayo Clinic, Johns Hopkins Hospital, and Cleveland Clinic helped define its clinical spectrum and natural history. Epidemiologic studies from cohorts like the Framingham Heart Study and longitudinal work at Karolinska Institutet and Harvard Medical School estimate rising prevalence with age; autopsy series from Oxford University and surgical series from Massachusetts General Hospital provide complementary prevalence data. Professional guidelines from bodies including the American Urological Association, the European Association of Urology, and the National Institute for Health and Care Excellence inform clinical pathways.

Signs and symptoms

Patients commonly report storage and voiding complaints: urinary frequency, nocturia, urgency, hesitancy, weak stream, intermittency, and incomplete emptying. Symptom quantification frequently uses validated instruments developed by researchers associated with University of Michigan and University College London, and outcome measures are deployed in trials run at centers like Stanford University and University of California, San Francisco. Acute urinary retention may present as sudden inability to void, a complication encountered in emergency departments at institutions such as Maimonides Medical Center and Mount Sinai Hospital. Symptom impact on quality of life has been evaluated in population surveys conducted with oversight from organizations such as the World Health Organization and the Centers for Disease Control and Prevention.

Causes and pathophysiology

The pathogenesis involves hormone-driven growth, stromal–epithelial interactions, and age-related tissue remodeling. Androgenic signaling mediated by testosterone and dihydrotestosterone, the enzyme 5α-reductase characterized in pharmacology labs at Pfizer and GlaxoSmithKline, and growth factors studied at National Institutes of Health laboratories contribute to prostatic enlargement. Molecular work from groups at Salk Institute and Cold Spring Harbor Laboratory elucidated pathways including androgen receptor signaling, fibroblast growth factor, and inflammatory cytokines first described in research from Johns Hopkins University School of Medicine. Vascular factors and metabolic syndrome associations were explored in epidemiologic research at Brown University and University of California, Los Angeles. Age remains the dominant risk correlate across cohorts studied at University of Cambridge and Imperial College London.

Diagnosis

Diagnosis integrates history, examination, urinary symptom scores, and adjunct testing used in clinics from Cleveland Clinic to Guy's and St Thomas' NHS Foundation Trust. Digital rectal examination assesses prostate size and nodularity; prostate-specific antigen testing, originated in studies at Roswell Park Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center, helps to exclude malignancy although it is not diagnostic for hyperplasia. Urinalysis screens for infection or hematuria in line with protocols from Beth Israel Deaconess Medical Center. Noninvasive uroflowmetry and postvoid residual measurement are available in urodynamic units such as those at University of Toronto and Karolinska University Hospital, while transrectal ultrasound and pelvic MRI—techniques advanced at Mayo Clinic and Johns Hopkins Hospital—can quantify gland volume and guide interventions. Cystoscopy is reserved for cases evaluated in operating suites at centers including Cleveland Clinic and UCLA Health.

Management and treatment

Management ranges from watchful waiting to medical therapy and surgical intervention. Conservative strategies and lifestyle counseling have been advocated in primary care settings affiliated with Kaiser Permanente and Veterans Health Administration. Pharmacologic options include alpha-1 blockers (drugs developed and marketed after trials at Merck and Boehringer Ingelheim), 5α-reductase inhibitors (agents with pivotal trials at GlaxoSmithKline), and phosphodiesterase-5 inhibitors investigated in studies at Columbia University. Minimally invasive therapies—such as transurethral microwave thermotherapy and prostatic urethral lift—originated from innovation at institutions like Mayo Clinic and companies spun out from Massachusetts Institute of Technology. Standard surgical approaches include transurethral resection of the prostate, first standardized in urology departments at University College Hospital and Addenbrooke's Hospital, and newer modalities such as holmium laser enucleation developed through collaborations at Karolinska Institutet and University of Vienna.

Complications and prognosis

Untreated obstruction can lead to recurrent urinary tract infections, bladder decompensation, hydronephrosis, and renal impairment—outcomes reported in nephrology series from Cleveland Clinic and Mayo Clinic. Acute urinary retention sometimes necessitates catheterization or emergent decompression as managed in emergency departments at Massachusetts General Hospital. Contemporary cohort studies from Johns Hopkins Hospital and randomized trials sponsored by organizations such as the National Institute of Diabetes and Digestive and Kidney Diseases show that medical therapy reduces symptom burden and lowers the risk of progression, while surgical therapy provides durable relief of obstruction and improves quality-adjusted survival in selected patients. Long-term prognosis depends on baseline severity, comorbidity profiles documented in studies from Stanford University Medical Center, and timely access to evidence-based care recommended by American College of Physicians and European Association of Urology.

Category:Urology